Limits...
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG - J. Pathol. (2015)

Bottom Line: Using a large cohort of human prostate tissues of different grades, in silico data, in vitro and ex vivo studies, we demonstrate the metabolic heterogeneity of PCa and its clinical relevance.We show an increased glycolytic phenotype in advanced stages of PCa and its correlation with poor prognosis.Finally, we present evidence supporting MCTs as suitable targets in PCa, affecting not only cancer cell proliferation and survival but also the expression of a number of hypoxia-inducible factor target genes associated with poor prognosis.

View Article: PubMed Central - PubMed

Affiliation: Uro-oncology Research Group, Cancer Research UK (CRUK) Cambridge Institute, Cambridge, UK.

Show MeSH

Related in: MedlinePlus

(A, B) Western blot analysis of MCT1 and MCT4, showing different levels of expression in different prostate cancer cell lines. (C–F) Effect of androgen stimulation and inhibition on MCTs expression: (C, D) plots from the expression array with androgen treatment time-course; (E–H) effect of hypoxic conditions (1% O2) on MCTs expression; levels of MCT1 (E, F) and MCT4 (G, H) in PCa cells under normoxic (NX) and hypoxic (HX) conditions; aata expressed as ± SD; n = 3; *p < 0.05. (I, J) Integrated Genome Browser view of ChIP-Seq enrichment profiles of SLC16A1 and SLC16A3 in LNCaP cell lines. (K) Venn diagram showing the overlap between genes expressed by LNCaP cell lines under different oxygen and hormone conditions
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4528232&req=5

fig05: (A, B) Western blot analysis of MCT1 and MCT4, showing different levels of expression in different prostate cancer cell lines. (C–F) Effect of androgen stimulation and inhibition on MCTs expression: (C, D) plots from the expression array with androgen treatment time-course; (E–H) effect of hypoxic conditions (1% O2) on MCTs expression; levels of MCT1 (E, F) and MCT4 (G, H) in PCa cells under normoxic (NX) and hypoxic (HX) conditions; aata expressed as ± SD; n = 3; *p < 0.05. (I, J) Integrated Genome Browser view of ChIP-Seq enrichment profiles of SLC16A1 and SLC16A3 in LNCaP cell lines. (K) Venn diagram showing the overlap between genes expressed by LNCaP cell lines under different oxygen and hormone conditions

Mentions: Since the androgen receptor (AR) is an important regulator of metabolic pathways in PCa, regulating the expression of various genes involved in metabolism [28], we sought to determine potential cross-regulation between MCTs and AR signalling. We found that MCT1 levels were higher in PC3 and LNCaP cells compared to DU145 and 22RV1 cell lines (Figure 5A). MCT4 protein was only present in the AR-negative cells, PC3 and DU145 (Figure 5B). In LNCaP cells treated with the synthetic androgen R1881, no major changes were observed for MCT1 and MCT4 mRNA expression levels during up to 24 h of treatment (Figure 5C, D). While MCT1 has emerged as a new anticancer target and a first MCT1 inhibitor is currently entering clinical trials [29,30], little is known about its regulation by typical parameters of the tumour microenvironment. Figure 5E–H shows the expression levels of MCTs in LNCaP and PC3 cell lines when grown under different oxygen conditions. The results clearly show an increase in MCTs expression with hypoxia, a typical feature of the tumour microenvironment. Figure 5K, L, shows a comparison of SLC16A1 and SLC16A3 peaks from ChIP-seq in LNCaP cell lines growing under different oxygen conditions. While no HIF-1α binding peaks are seen for SLC16A1 (Figure 5I), there is a clear HIF1A binding peak upstream of the SLC16A3 locus (Figure 5J). Figure 5M shows a Venn diagram demonstrating the overlap between groups of genes expressed by LNCaP cells under different conditions (M Tran, unpublished results). It is interesting to observe that SLC16A3, LDHA, PDK1 and CA9, previously associated with poor prognosis, appear in the group of genes expressed when hypoxia is present, with or without androgen stimulation.


A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG - J. Pathol. (2015)

(A, B) Western blot analysis of MCT1 and MCT4, showing different levels of expression in different prostate cancer cell lines. (C–F) Effect of androgen stimulation and inhibition on MCTs expression: (C, D) plots from the expression array with androgen treatment time-course; (E–H) effect of hypoxic conditions (1% O2) on MCTs expression; levels of MCT1 (E, F) and MCT4 (G, H) in PCa cells under normoxic (NX) and hypoxic (HX) conditions; aata expressed as ± SD; n = 3; *p < 0.05. (I, J) Integrated Genome Browser view of ChIP-Seq enrichment profiles of SLC16A1 and SLC16A3 in LNCaP cell lines. (K) Venn diagram showing the overlap between genes expressed by LNCaP cell lines under different oxygen and hormone conditions
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4528232&req=5

fig05: (A, B) Western blot analysis of MCT1 and MCT4, showing different levels of expression in different prostate cancer cell lines. (C–F) Effect of androgen stimulation and inhibition on MCTs expression: (C, D) plots from the expression array with androgen treatment time-course; (E–H) effect of hypoxic conditions (1% O2) on MCTs expression; levels of MCT1 (E, F) and MCT4 (G, H) in PCa cells under normoxic (NX) and hypoxic (HX) conditions; aata expressed as ± SD; n = 3; *p < 0.05. (I, J) Integrated Genome Browser view of ChIP-Seq enrichment profiles of SLC16A1 and SLC16A3 in LNCaP cell lines. (K) Venn diagram showing the overlap between genes expressed by LNCaP cell lines under different oxygen and hormone conditions
Mentions: Since the androgen receptor (AR) is an important regulator of metabolic pathways in PCa, regulating the expression of various genes involved in metabolism [28], we sought to determine potential cross-regulation between MCTs and AR signalling. We found that MCT1 levels were higher in PC3 and LNCaP cells compared to DU145 and 22RV1 cell lines (Figure 5A). MCT4 protein was only present in the AR-negative cells, PC3 and DU145 (Figure 5B). In LNCaP cells treated with the synthetic androgen R1881, no major changes were observed for MCT1 and MCT4 mRNA expression levels during up to 24 h of treatment (Figure 5C, D). While MCT1 has emerged as a new anticancer target and a first MCT1 inhibitor is currently entering clinical trials [29,30], little is known about its regulation by typical parameters of the tumour microenvironment. Figure 5E–H shows the expression levels of MCTs in LNCaP and PC3 cell lines when grown under different oxygen conditions. The results clearly show an increase in MCTs expression with hypoxia, a typical feature of the tumour microenvironment. Figure 5K, L, shows a comparison of SLC16A1 and SLC16A3 peaks from ChIP-seq in LNCaP cell lines growing under different oxygen conditions. While no HIF-1α binding peaks are seen for SLC16A1 (Figure 5I), there is a clear HIF1A binding peak upstream of the SLC16A3 locus (Figure 5J). Figure 5M shows a Venn diagram demonstrating the overlap between groups of genes expressed by LNCaP cells under different conditions (M Tran, unpublished results). It is interesting to observe that SLC16A3, LDHA, PDK1 and CA9, previously associated with poor prognosis, appear in the group of genes expressed when hypoxia is present, with or without androgen stimulation.

Bottom Line: Using a large cohort of human prostate tissues of different grades, in silico data, in vitro and ex vivo studies, we demonstrate the metabolic heterogeneity of PCa and its clinical relevance.We show an increased glycolytic phenotype in advanced stages of PCa and its correlation with poor prognosis.Finally, we present evidence supporting MCTs as suitable targets in PCa, affecting not only cancer cell proliferation and survival but also the expression of a number of hypoxia-inducible factor target genes associated with poor prognosis.

View Article: PubMed Central - PubMed

Affiliation: Uro-oncology Research Group, Cancer Research UK (CRUK) Cambridge Institute, Cambridge, UK.

Show MeSH
Related in: MedlinePlus